What is Lifesci Capital’s Estimate for CLDX FY2025 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at Lifesci Capital lowered their FY2025 earnings per share estimates for Celldex Therapeutics in a research note issued to investors on Monday, November 10th. Lifesci Capital analyst S. Slutsky now anticipates that the biopharmaceutical company will earn ($3.31) per share for the year, down from their prior forecast of ($3.07). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Lifesci Capital also issued estimates for Celldex Therapeutics’ Q4 2025 earnings at ($1.03) EPS.

CLDX has been the subject of several other reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $62.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. Citigroup dropped their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. Mizuho started coverage on Celldex Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $48.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright cut their target price on Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.

Celldex Therapeutics Stock Down 0.1%

Celldex Therapeutics stock traded down $0.02 during mid-day trading on Thursday, hitting $24.23. 133,419 shares of the company were exchanged, compared to its average volume of 1,015,047. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $29.05. The company has a market capitalization of $1.61 billion, a PE ratio of -8.07 and a beta of 1.36. The business has a fifty day moving average of $25.49 and a 200 day moving average of $22.82.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Celldex Therapeutics in the first quarter valued at approximately $269,000. GSA Capital Partners LLP acquired a new stake in shares of Celldex Therapeutics in the 1st quarter valued at approximately $1,131,000. Vanguard Group Inc. boosted its position in Celldex Therapeutics by 0.4% during the first quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company’s stock worth $70,757,000 after purchasing an additional 16,440 shares in the last quarter. Deutsche Bank AG raised its stake in Celldex Therapeutics by 13.8% in the 1st quarter. Deutsche Bank AG now owns 138,289 shares of the biopharmaceutical company’s stock valued at $2,510,000 after purchasing an additional 16,788 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Celldex Therapeutics by 24.6% during the first quarter. Invesco Ltd. now owns 52,443 shares of the biopharmaceutical company’s stock worth $952,000 after purchasing an additional 10,342 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.